ClinicalTrials.Veeva

Menu

Glycemic Variability: Prognostic Impact on Acute Ischemic Stroke (GLIAS-III)

I

Instituto de Investigación Hospital Universitario La Paz

Status

Unknown

Conditions

Brain Ischemia
Hyperglycemia
Glycemic Variability

Study type

Observational

Funder types

Other

Identifiers

NCT04001049
GLIAS-III

Details and patient eligibility

About

This is a multicenter observational clinical study in patients with acute ischemic stroke. The main objective is to evaluate the impact of glycemic variability (GV) on stroke outcome (mortality, functional recovery) of patients with acute ischemic stroke. Glycemic variability will be assessed using a subcutaneous device for continuous glycaemia motorization during 96 hours; also capillar glycaemia will be measured every 6 hours.

Full description

10 different hospitals in Spain will participate in this study, recruiting a total of 340 patients. Once the informed consent form is signed, the subcutaneous device for continuous glycaemia motorization will be implanted and demographic, comorbidities and treatments of every patient will be registered. During the first 96 hours, capillar glycaemia, NIHSS scale, HbA1C levels, cerebral recanalization treatment and glycaemia correcting treatments will also be reported. In the following days (7, 30 and 90 days after stroke) modified Rankin Scale, NIHSS scale and stroke secondary prevention treatments will be evaluated. At day 90, a new measure of HbA1C will be done.

Enrollment

340 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • > 18 years old
  • Inclusion less than 24 hours from ischemic stroke
  • Functional independence prior to stroke
  • Signed informed consent

Exclusion criteria

  • Transient cerebral ischemia
  • Prevision of need to perform a magnetic resonance within the first 96 hours from inclusion
  • Concomitant severe or deadly disease that may interfere with study follow-up during 3 months from stroke
  • Current drug or alcohol abuse that may interfere with study follow-up
  • Participation in a clinical trial

Trial contacts and locations

1

Loading...

Central trial contact

Elena de Celis Ruiz; Blanca Fuentes Gimeno

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems